1. Home
  2. PMEC vs CALC Comparison

PMEC vs CALC Comparison

Compare PMEC & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primech Holdings Ltd.

PMEC

Primech Holdings Ltd.

HOLD

Current Price

$0.63

Market Cap

18.6M

Sector

N/A

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$1.97

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMEC
CALC
Founded
1984
2011
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.6M
19.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PMEC
CALC
Price
$0.63
$1.97
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
84.1K
239.3K
Earning Date
07-24-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.44
52 Week High
$2.44
$7.20

Technical Indicators

Market Signals
Indicator
PMEC
CALC
Relative Strength Index (RSI) 63.59 64.98
Support Level $0.51 $0.53
Resistance Level $0.80 $2.39
Average True Range (ATR) 0.07 0.19
MACD 0.01 -0.01
Stochastic Oscillator 68.75 16.59

Price Performance

Historical Comparison
PMEC
CALC

About PMEC Primech Holdings Ltd.

Primech Holdings Ltd is a cleaning business. The Company operates in two segments: commercial cleaning services and robotics. The Company is an established technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The Company generates revenue from services, which include services for general cleaning and maintenance of public and private facilities; cleaning of kitchen facilities of healthcare facilities, hotels and restaurants; and the supply of ad hoc customer; and cleaning services to offices.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: